HK1154910A1 - Tests to predict responsiveness of cancer patients to chemotherapy treatment options - Google Patents
Tests to predict responsiveness of cancer patients to chemotherapy treatment optionsInfo
- Publication number
- HK1154910A1 HK1154910A1 HK11109113.0A HK11109113A HK1154910A1 HK 1154910 A1 HK1154910 A1 HK 1154910A1 HK 11109113 A HK11109113 A HK 11109113A HK 1154910 A1 HK1154910 A1 HK 1154910A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tests
- cancer patients
- treatment options
- chemotherapy treatment
- predict responsiveness
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5257308P | 2008-05-12 | 2008-05-12 | |
US5718208P | 2008-05-29 | 2008-05-29 | |
PCT/US2009/043667 WO2009140304A1 (fr) | 2008-05-12 | 2009-05-12 | Tests pour prédire une sensibilité de patients atteints de cancer à des options de traitement de chimiothérapie |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1154910A1 true HK1154910A1 (en) | 2012-05-04 |
Family
ID=41319028
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11109113.0A HK1154910A1 (en) | 2008-05-12 | 2011-08-29 | Tests to predict responsiveness of cancer patients to chemotherapy treatment options |
HK13107812.6A HK1180727A1 (en) | 2008-05-12 | 2011-08-29 | Tests to predict responsiveness of cancer patients to chemotherapy treatment options |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13107812.6A HK1180727A1 (en) | 2008-05-12 | 2011-08-29 | Tests to predict responsiveness of cancer patients to chemotherapy treatment options |
Country Status (7)
Country | Link |
---|---|
US (1) | US20090311702A1 (fr) |
EP (5) | EP2641977B1 (fr) |
CA (1) | CA2723972A1 (fr) |
DK (2) | DK2294215T3 (fr) |
ES (2) | ES2403220T3 (fr) |
HK (2) | HK1154910A1 (fr) |
WO (1) | WO2009140304A1 (fr) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2799555B1 (fr) * | 2002-03-13 | 2017-02-22 | Genomic Health, Inc. | Profilage de l'expression génétique dans des tissus de tumeurs prélevées par biopsie |
US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
ES2609234T3 (es) | 2003-06-24 | 2017-04-19 | Genomic Health, Inc. | Predicción de la probabilidad de recidiva de cáncer |
WO2005100606A2 (fr) | 2004-04-09 | 2005-10-27 | Genomic Health, Inc. | Marqueurs d'expression genique permettant de predire la reponse a la chimiotherapie |
WO2006052862A1 (fr) * | 2004-11-05 | 2006-05-18 | Genomic Health, Inc. | Prediction de reaction a la chimiotherapie au moyen de marqueurs d'expression genique |
IL282783B2 (en) | 2006-05-18 | 2023-09-01 | Caris Mpi Inc | A system and method for determining a personalized medical intervention for a disease stage |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
EP3075864A1 (fr) * | 2008-10-14 | 2016-10-05 | Caris MPI, Inc. | Gène et protéine exprimées par des gènes cibles représentant des profils de biomarqueurs et ensembles de signature par type de tumeurs |
GB2463401B (en) | 2008-11-12 | 2014-01-29 | Caris Life Sciences Luxembourg Holdings S A R L | Characterizing prostate disorders by analysis of microvesicles |
US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
US8980564B2 (en) | 2009-11-20 | 2015-03-17 | The Governors Of The University Of Alberta | Predictive markers for taxane responsiveness and methods of use thereof |
US20130005597A1 (en) * | 2009-12-18 | 2013-01-03 | Rathmell W Kimryn | Methods and compositions for analysis of clear cell renal cell carcinoma (ccrcc) |
US20130011393A1 (en) * | 2010-01-12 | 2013-01-10 | Johnathan Mark Lancaster | Bad pathway gene signature |
KR20130056855A (ko) | 2010-03-01 | 2013-05-30 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 치료진단용 생물학적 지표들 |
AU2011237669B2 (en) | 2010-04-06 | 2016-09-08 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for disease |
US20120053253A1 (en) | 2010-07-07 | 2012-03-01 | Myriad Genetics, Incorporated | Gene signatures for cancer prognosis |
WO2012030840A2 (fr) | 2010-08-30 | 2012-03-08 | Myriad Genetics, Inc. | Signatures génétiques pour le diagnostic et le pronostic du cancer |
WO2012097276A2 (fr) * | 2011-01-13 | 2012-07-19 | Expression Pathology, Inc. | Dosage par srm/mrm de la protéine 11 de type bcl-2 |
WO2012145575A2 (fr) | 2011-04-21 | 2012-10-26 | Children's Hospital Medical Center | Thérapie pour la leucémie |
US10342767B2 (en) | 2011-04-21 | 2019-07-09 | Children's Hospital Medical Center | Therapy for kinase-dependent malignancies |
CN102312002A (zh) * | 2011-09-20 | 2012-01-11 | 李艳 | 一种快速检测BRCA1基因mRNA表达量的试剂盒 |
WO2013130465A2 (fr) * | 2012-02-27 | 2013-09-06 | Genomic Health, Inc. | Marqueurs d'expression génétique utilisés pour prédire l'efficacité d'un médicament antinéoplasique à base de platine |
WO2013170174A1 (fr) * | 2012-05-10 | 2013-11-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Méthode de diagnostic, de traitement et de détermination de la progression et de la survie de cellules cancéreuses à l'aide de la signature génique de l'antagoniste bcl-2 de la voie de la mort cellulaire (bad) |
CN102965433A (zh) * | 2012-09-29 | 2013-03-13 | 李艳 | 一种检测M BCR融合基因mRNA表达量的试剂盒 |
EP2920322B1 (fr) | 2012-11-16 | 2023-01-11 | Myriad Genetics, Inc. | Signatures génétiques utilisées en vue du pronostic d'un cancer |
WO2014092572A1 (fr) * | 2012-12-12 | 2014-06-19 | Universiteit Leiden | Méthodes améliorées de traitement du cancer à l'aide d'un agent génotoxique |
CA2912547A1 (fr) * | 2013-07-03 | 2015-01-08 | F. Hoffmann-La Roche Ag | Expression genique a base d'arnm pour la personnalisation de la therapie anticancereuse d'un patient par un antagoniste de mdm2 |
US9657351B2 (en) | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
CA2944401A1 (fr) * | 2014-04-03 | 2015-10-08 | Invictus Oncology Pvt. Ltd. | Agents therapeutiques combinatoires supramoleculaires |
CA2947624A1 (fr) | 2014-05-13 | 2015-11-19 | Myriad Genetics, Inc. | Signatures genetiques utilisees en vue du pronostic d'un cancer |
US20170079979A1 (en) * | 2014-06-02 | 2017-03-23 | Children's Hospital Medical Center | Therapy for solid tumors |
GB201501930D0 (en) * | 2015-02-05 | 2015-03-25 | Univ London Queen Mary | Biomarkers for pancreatic cancer |
US11136583B2 (en) | 2017-01-10 | 2021-10-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
WO2019217581A2 (fr) * | 2018-05-11 | 2019-11-14 | Baylor College Of Medicine | Perte de mutl prédisant la sensibilité à des inhibiteurs de cdk4/6 dans le cancer |
US20210317535A1 (en) * | 2018-08-29 | 2021-10-14 | The Regents Of The University Of Michigan | Methods of determining treatment consisting of radiation therapy and/or alkylating chemotherapy in patients suffering from cancer |
CN109439755A (zh) * | 2018-11-30 | 2019-03-08 | 广东腾飞基因科技股份有限公司 | 一种用于检测乳腺癌相关基因表达水平的试剂盒 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6627733B2 (en) * | 1993-06-14 | 2003-09-30 | Jeffrey D. Johnson | Receptor tyrosine kinase with a discoidin-type binding domain |
JP2000038909A (ja) | 1998-07-22 | 2000-02-08 | Mitsubishi Electric Corp | バルブタイミング可変装置 |
WO2002033520A2 (fr) | 2000-10-18 | 2002-04-25 | Genomic Health, Inc. | Systeme d'information sur le profil genomique et procede associe |
EP2799555B1 (fr) | 2002-03-13 | 2017-02-22 | Genomic Health, Inc. | Profilage de l'expression génétique dans des tissus de tumeurs prélevées par biopsie |
JP2007507222A (ja) * | 2003-05-28 | 2007-03-29 | ゲノミック ヘルス, インコーポレイテッド | 化学療法に対する応答を予測するための遺伝子発現マーカー |
ES2609234T3 (es) | 2003-06-24 | 2017-04-19 | Genomic Health, Inc. | Predicción de la probabilidad de recidiva de cáncer |
CA2531967C (fr) | 2003-07-10 | 2013-07-16 | Genomic Health, Inc. | Algorithme de profile d'expression et test du pronostic du cancer |
US20050095634A1 (en) | 2003-10-16 | 2005-05-05 | Genomic Health Inc. | qRT-PCR assay system for gene expression profiling |
FR2863275B1 (fr) * | 2003-12-09 | 2007-08-10 | Biomerieux Sa | Procede pour le diagnostic/pronostic du cancer du sein |
WO2005100606A2 (fr) | 2004-04-09 | 2005-10-27 | Genomic Health, Inc. | Marqueurs d'expression genique permettant de predire la reponse a la chimiotherapie |
US7587279B2 (en) | 2004-07-06 | 2009-09-08 | Genomic Health | Method for quantitative PCR data analysis system (QDAS) |
WO2006052862A1 (fr) * | 2004-11-05 | 2006-05-18 | Genomic Health, Inc. | Prediction de reaction a la chimiotherapie au moyen de marqueurs d'expression genique |
CA2613290A1 (fr) * | 2005-05-27 | 2007-05-24 | Aurelium Biopharma Inc. | Micromatrice d'adn focalisee et procedes de diagnostic de resistance aux medicaments chimiotherapeutiques dans une cellule cancereuse |
CA2611728A1 (fr) * | 2005-06-08 | 2006-12-14 | Millennium Pharmaceuticals, Inc. | Methode d'identification, d'evaluation et de traitement de patients suivant un traitement anticancereux |
EP1907858A4 (fr) * | 2005-06-13 | 2009-04-08 | Univ Michigan | Compositions et procedes de traitement et de diagnostic du cancer |
US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
WO2007028146A2 (fr) * | 2005-09-01 | 2007-03-08 | Precision Therapeutics, Inc. | Tests de chimiosensibilite faisant appel a des cellules tumorales presentant des caracteristiques phenotypiques persistantes |
WO2007085497A2 (fr) * | 2006-01-30 | 2007-08-02 | Epigenomics Ag | Marqueurs de prévision des résultats d'un traitement à l'anthracycline |
US20090125247A1 (en) * | 2007-08-16 | 2009-05-14 | Joffre Baker | Gene expression markers of recurrence risk in cancer patients after chemotherapy |
-
2009
- 2009-05-12 EP EP13172854.5A patent/EP2641977B1/fr not_active Not-in-force
- 2009-05-12 ES ES09747388T patent/ES2403220T3/es active Active
- 2009-05-12 EP EP20130172903 patent/EP2641978A1/fr not_active Withdrawn
- 2009-05-12 WO PCT/US2009/043667 patent/WO2009140304A1/fr active Application Filing
- 2009-05-12 EP EP12195318.6A patent/EP2568053B1/fr active Active
- 2009-05-12 CA CA2723972A patent/CA2723972A1/fr not_active Abandoned
- 2009-05-12 US US12/464,797 patent/US20090311702A1/en not_active Abandoned
- 2009-05-12 EP EP13159677.7A patent/EP2607497B1/fr not_active Not-in-force
- 2009-05-12 EP EP09747388A patent/EP2294215B1/fr active Active
- 2009-05-12 ES ES12195318.6T patent/ES2482692T3/es active Active
- 2009-05-12 DK DK09747388.8T patent/DK2294215T3/da active
- 2009-05-12 DK DK12195318.6T patent/DK2568053T3/da active
-
2011
- 2011-08-29 HK HK11109113.0A patent/HK1154910A1/en unknown
- 2011-08-29 HK HK13107812.6A patent/HK1180727A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2641978A1 (fr) | 2013-09-25 |
HK1180727A1 (en) | 2013-10-25 |
CA2723972A1 (fr) | 2009-11-19 |
ES2482692T3 (es) | 2014-08-04 |
EP2641977B1 (fr) | 2014-09-03 |
EP2294215A4 (fr) | 2011-06-29 |
EP2641977A1 (fr) | 2013-09-25 |
DK2294215T3 (da) | 2013-04-22 |
EP2568053A1 (fr) | 2013-03-13 |
EP2294215B1 (fr) | 2013-01-16 |
EP2294215A1 (fr) | 2011-03-16 |
DK2568053T3 (da) | 2014-07-21 |
WO2009140304A1 (fr) | 2009-11-19 |
ES2403220T3 (es) | 2013-05-16 |
US20090311702A1 (en) | 2009-12-17 |
EP2607497A1 (fr) | 2013-06-26 |
EP2568053B1 (fr) | 2014-04-16 |
EP2607497B1 (fr) | 2014-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1154910A1 (en) | Tests to predict responsiveness of cancer patients to chemotherapy treatment options | |
IL276487B (en) | Methods for predicting clinical outcome of cancer | |
HK1178602A1 (en) | Methods for predicting response of triple-negative breast cancer to therapy | |
IL218575A0 (en) | Treatment of cancer | |
EP2512375A4 (fr) | Dispositif d'expansion pour le traitement des voies de passage vasculaires | |
IL229878A (en) | Cancer Treatment Compounds | |
EP2558599A4 (fr) | Procédés d'évaluation de réponse à thérapie anticancéreuse | |
IL217291A0 (en) | Exosome based treatment of cancer | |
DK3130923T3 (da) | Terapeutiske fremgangsmåder i forbindelse med cancerstamceller | |
SG10201508495VA (en) | Combination treatment of cancer | |
ZA201300218B (en) | Treatment of blood cancer | |
EP2461814A4 (fr) | Traitement du cancer de la prostate | |
EP2385114A4 (fr) | Diagnostic de traitement d'un cancer à l'aide d'un anticorps anti-tm4sf20 | |
EP2652156A4 (fr) | Procédé de détection de la résistance vis-à-vis d'une thérapie anticancéreuse | |
PL388252A1 (pl) | Terapia skojarzona raka jelita grubego | |
GB0916686D0 (en) | Treatment of cancer | |
EP2294224A4 (fr) | Procédés de prédiction de la réponse tumorale à une chimiothérapie, et de sélection d'un traitement tumoral | |
IL215199A0 (en) | Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer | |
EP2214485A4 (fr) | Méthodes de traitement du cancer | |
GB0712956D0 (en) | Therapeutic uses of cannabinoids | |
GB0921757D0 (en) | Treatment of cancer | |
GB0906490D0 (en) | Use of tetanolic for treatment of breast cancer | |
IL223237A0 (en) | Diagnosis of cancer | |
GB201017354D0 (en) | Treatment of cancer | |
GB0712513D0 (en) | Treatment of cancer |